The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 10, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ravi P Agrawal, trustee of Ravi Agrawal Trust and a promoter of Ajanta Pharma, has released a pledge on 1,30,000 shares (0.10% of total share capital) on 5 September 2025. The shares were pledged with Barclays Investment and Loans (India) Private Limited, and the reason given for the release is re-financing. Post-release, the encumbered shares under Ravi Agrawal Trust stand at 58,77,642 shares (4.70% of capital), reduced from 60,07,642 shares (4.81%) before the release. His total promoter holding remains unchanged at 1,62,42,904 shares (13.00%).
This is a routine re-financing action by the promoter, reducing encumbered shares marginally. There is no change in promoter ownership or any stake sale, so it has no material impact on the stock price. It signals that the promoter is restructuring debt rather than indicating any stress or exit.